MLIP: A Protein Implicated in Cancer and Angiogenesis (G90523)

Target Name: MLIP

NCBI ID: G90523

MLIP

MLIP: A Protein Implicated in Cancer and Angiogenesis

MLIP, or MLIP variant 2, is a protein that is expressed in the human placenta and has been shown to play a role in the development and progression of various diseases, including cancer. The exact function of MLIP is not yet fully understood, but it is thought to be involved in the regulation of cell growth, apoptosis, and angiogenesis.

One of the key features of MLIP is its ability to induce cell death, either through apoptosis or through a process called necroptosis. This is done through the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the development of diseases.

In addition to its role in cell death, MLIP has also been shown to play a key role in the regulation of angiogenesis, the process by which new blood vessels are formed in the body. This is done through the production of growth factors, such as vascular endothelial growth factor (VEGF), which is essential for the formation of new blood vessels.

The exact mechanism by which MLIP promotes angiogenesis is not yet fully understood, but it is thought to be involved in the regulation of the Wnt signaling pathway, a pathway that is involved in the development and maintenance of blood vessels.

One of the potential applications of MLIP is as a drug target or biomarker for various diseases, including cancer. By inhibiting the activity of MLIP, it may be possible to treat diseases that are characterized by the overproduction of ROS and the failure of angiogenesis.

In addition to its potential as a drug target, MLIP is also of interest as a biomarker for certain diseases. For example, MLIP has been shown to be elevated in the blood of individuals with certain forms of cancer, such as breast cancer and lung cancer. This suggests that it may be a useful biomarker for these diseases, and that its levels may be a useful diagnostic indicator.

Overall, MLIP is a protein that has the potential to be a drug target or biomarker for various diseases. Further research is needed to fully understand its function and to develop effective treatments for the various conditions that are associated with its overproduction or dysfunction.

Protein Name: Muscular LMNA Interacting Protein

Functions: Required for myoblast differentiation into myotubes, possibly acting as a transcriptional regulator of the myogenic program (By similarity). Required for cardiac adaptation to stress through integrated regulation of the AKT/mTOR pathways and FOXO1. Regulates cardiac homeostasis and plays a role in the protection against cardiac hypertrophy (By similarity). Binds chromatin (By similarity). May act as a transcriptional cofactor for ISL1, repressing its transcriptional activity (By similarity). May also repress MYOCD transcriptional activity (By similarity)

The "MLIP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MLIP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets